According to the researchers, the strong response to one dose of the vaccine among those previously infected regardless of the duration between infection and vaccination is good news.
The study assessed efficacy of the vaccine during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely.
Since low levels of T cells are a hallmark of COVID-19, it is of interest to understand the role of one type of immune cell, monocytic myeloid-derived suppressor cells, or M-MDSC.
For the study, the team surveyed 16 viral RNA binding proteins in human lung epithelial cells.
Doctors are increasingly discussing with fellow colleagues their doubts regarding the safety aspect of the vaccines approved in India, according to reports.
'Although these vaccines have been made in record time, the testing methodology and procedures have not been compromised.'
To the question that received 8,723 responses, only 26 per cent of citizens said that they will get it as soon as it becomes available via private or any healthcare channels.
'The evaluation of Covaxin has resulted in several unique product characteristics including long term persistence of immune responses to multiple viral proteins.'
The Hyderabad-based vaccine maker expressed its delight after the Drug Controller General of India (DCGI) granted permission for the emergency use of its COVID-19 vaccine.
About 755 participants have been vaccinated in phase 1 & 2 clinical trials and no serious adverse events have been reported to be related to the vaccine in phase 1 and 2 clinical trials.